FDA Approves Breakthrough Durysta Sustained-Release Glaucoma Implant


■ The FDA has approved Allergan’s New Drug Application for Durysta, a prostaglandin analog 10-μg bimatoprost sustained-release implant for intracameral administration, formerly known as Bimatoprost SR. Durysta is the first intracameral, biodegradable sustained-release implant indicated to reduce IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Read this full story at